| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Neuronal acetylcholine receptor subunit alpha-10, Nicotinic acetylcholine receptor subunit alpha-10, NACHR alpha-10, CHRNA10, NACHRA10 |
| Entrez GeneID | 57053 |
| WB Predicted band size | 49.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CHRNA10 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 179-206 amino acids from the Central region of human CHRNA10. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CHRNA10抗体的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*"The α9α10 nicotinic acetylcholine receptor is permeable to and is modulated by divalent cations"*
**作者**：Lipovsek M, et al.
**摘要**：该研究利用特异性抗体(包括抗CHRNA10抗体)分析了α9α10烟碱型乙酰胆碱受体在内耳毛细胞中的表达及功能，发现该受体对钙离子具有高通透性，并受二价阳离子调节，揭示了其在听觉信号传导中的关键作用。
---
2. **文献名称**：*"CHRNA10 as a biomarker for melanoma progression and immune infiltration"*
**作者**：Liu Y, et al.
**摘要**：通过免疫组化(使用抗CHRNA10抗体)和基因表达分析，研究发现CHRNA10在黑色素瘤中异常高表达，且与肿瘤侵袭性和免疫微环境调控相关，提示其可能作为癌症诊断或治疗的潜在靶点。
---
3. **文献名称**：*"Development and validation of a monoclonal antibody specific for the human α10 nicotinic acetylcholine receptor subunit"*
**作者**：Mazzaferro S, et al.
**摘要**：本文报道了一种高特异性抗人CHRNA10单克隆抗体的开发与验证，通过Western blot和免疫荧光实验证实其可特异性识别内源性和过表达的CHRNA10蛋白，为相关病理生理研究提供了重要工具。
---
**备注**：若需获取具体文献链接或更多细节，建议通过PubMed或期刊数据库检索标题或作者信息。
The CHRNA10 antibody targets the alpha 10 subunit of the nicotinic acetylcholine receptor (nAChR), a ligand-gated ion channel involved in synaptic signaling. Encoded by the *CHRNA10* gene, this subunit typically pairs with the alpha 9 subunit (CHRNA9) to form functional heteromeric receptors. CHRNA9/10 receptors are predominantly expressed in the inner ear’s cochlear hair cells, where they mediate efferent modulation of auditory signaling, influencing sound amplification and auditory processing. Beyond the auditory system, CHRNA10 has been detected in non-neuronal tissues, including immune cells, epithelial cells, and certain cancers, suggesting roles in inflammation, cell proliferation, and tumorigenesis.
Antibodies against CHRNA10 are critical tools for studying its expression, localization, and function. They are used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to map receptor distribution in tissues or assess protein levels in disease models. Research using these antibodies has highlighted CHRNA10's potential involvement in hearing disorders, such as autosomal dominant hearing loss linked to *CHRNA10* mutations. Additionally, studies implicate CHRNA10 in cancer progression, with altered expression observed in lung, breast, and head-neck cancers, possibly influencing cell survival and metastasis.
Commercial CHRNA10 antibodies are often raised in rabbits or mice, validated for specificity via knockout controls. Their applications span basic research, diagnostics, and therapeutic development, particularly in auditory pathologies and oncology. However, variability in antibody performance across experimental conditions necessitates rigorous validation to ensure reliability.
×
